Journal of Pharmacology and Experimental Therapeutics
July 2016
J M Witkin, J A Monn, D D Schoepp et al.
Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD). Although the mechanisms underlying these effects are not fully established, inquiry to date has focused on the triggering of synaptogenesis transduction pathways via glutamatergic mechanisms. Preclinical data suggest that blockade of metabotropic glutamate (mGlu2/3) receptors shares many...
International Journal of Advanced Research
June 30, 2016
Samar Adel Asker, Shireen A. Mazroa, Youmna Sabri
Background:- Ketamine is commonly used as a dissociative anesthetic drug. However, some clinical studies suggested that ketamine ameliorated depressive symptoms in patients with major depression. Therefore,
arXiv Preprint Archive
June 15, 2016
Eduardo C. Padovani
preprint
One of the main goals of neuroscience is to understand how an organism's cognitive capacities or physiological states are potentially related to brain activities that involve the interaction of multiple brain structures and cortical areas. A key feature of functional brain networks is that they are modularly structured, and this modular architecture is regarded as accounting for a range of...
PLoS One
June 14, 2016
Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun et al.
153 citations
In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as 'designer drugs' and compared them to the parent substances via the resources of the National Institute of Mental Health Psychoactive Drug Screening Program. The ketamine analogues methoxetamine ((RS)-2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone) and 3-MeO-PCE...
Psychopharmacology
June 11, 2016
K. Podkowa, Bartłomiej Pochwat, P. Brański et al.
Numerous preclinical and clinical studies have reported the rapid and sustained antidepressant effects of the NMDA receptor antagonist ketamine. Because ketamine induces several undesirable and dangerous effects, a variety of strategies have been suggested to avoid such effects. Here, we propose to enhance the sub-effective doses of ketamine by co-administration with the group II metabotropic...
Psychological Medicine
June 10, 2016
Kenji Hashimoto
54 citations
Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity Published online by Cambridge University Press: 10 June 2016 K. Hashimoto Show author details K.
The Journal of Clinical Psychiatry
June 2016
Dawn F. Ionescu, Michaela B Swee, Kara J. Pavone et al.
Ketamine rapidly reduces thoughts of suicide in patients with treatment-resistant depression who are at low risk for suicide. However, the extent to which ketamine reduces thoughts of suicide in depressed patients with current suicidal ideation remains unknown. Between April 2012 and October 2013, 14 outpatients with DSM-IV-diagnosed major depressive disorder were recruited for the presence of...
Therapeutic Advances in Psychopharmacology
June 2016
John Muller, Sahana Pentyala, James Dilger et al.
Recent evidence has suggested that the N-methyl-D-aspartate receptor antagonist ketamine shows significant therapeutic effects in major depression and bipolar disorder. This effect is especially important in treatment-resistant depression and depression with suicidal ideation. In this review we explain the mechanism of action, drug efficacy, and the side effects of ketamine; the antidepressive...
Psychopharmacology
June 1, 2016
Anna Mutti, Sonia Aroni, Paola Fadda et al.
Recently, an increasing number of emergency cases due to a novel ketamine-like drug, methoxetamine (MXE), were reported in several countries. However, very little is known about the neuropsychopharmacological and reinforcing profile of this compound. Our study aims to investigate the effects of MXE on self-administration (SA) behaviour in comparison to ketamine and on dopaminergic transmission....
Psychiatry Research
May 30, 2016
Chun Yang, Mei Han, Ji-Chun Zhang et al.
Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of...